1. Home
  2. GNPX vs ZBAI Comparison

GNPX vs ZBAI Comparison

Compare GNPX & ZBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNPX
  • ZBAI
  • Stock Information
  • Founded
  • GNPX 2009
  • ZBAI 2015
  • Country
  • GNPX United States
  • ZBAI United States
  • Employees
  • GNPX N/A
  • ZBAI N/A
  • Industry
  • GNPX Biotechnology: Pharmaceutical Preparations
  • ZBAI Professional Services
  • Sector
  • GNPX Health Care
  • ZBAI Consumer Discretionary
  • Exchange
  • GNPX Nasdaq
  • ZBAI Nasdaq
  • Market Cap
  • GNPX 5.5M
  • ZBAI 6.5M
  • IPO Year
  • GNPX 2018
  • ZBAI N/A
  • Fundamental
  • Price
  • GNPX $0.25
  • ZBAI $9.32
  • Analyst Decision
  • GNPX
  • ZBAI
  • Analyst Count
  • GNPX 0
  • ZBAI 0
  • Target Price
  • GNPX N/A
  • ZBAI N/A
  • AVG Volume (30 Days)
  • GNPX 24.1M
  • ZBAI 39.5K
  • Earning Date
  • GNPX 11-12-2025
  • ZBAI 11-12-2025
  • Dividend Yield
  • GNPX N/A
  • ZBAI N/A
  • EPS Growth
  • GNPX N/A
  • ZBAI N/A
  • EPS
  • GNPX N/A
  • ZBAI N/A
  • Revenue
  • GNPX N/A
  • ZBAI $720,000.00
  • Revenue This Year
  • GNPX N/A
  • ZBAI N/A
  • Revenue Next Year
  • GNPX N/A
  • ZBAI N/A
  • P/E Ratio
  • GNPX N/A
  • ZBAI N/A
  • Revenue Growth
  • GNPX N/A
  • ZBAI 44.00
  • 52 Week Low
  • GNPX $0.14
  • ZBAI $4.83
  • 52 Week High
  • GNPX $3.97
  • ZBAI $45.00
  • Technical
  • Relative Strength Index (RSI)
  • GNPX 55.11
  • ZBAI 62.64
  • Support Level
  • GNPX $0.22
  • ZBAI $8.45
  • Resistance Level
  • GNPX $0.32
  • ZBAI $11.00
  • Average True Range (ATR)
  • GNPX 0.05
  • ZBAI 1.11
  • MACD
  • GNPX 0.01
  • ZBAI 0.46
  • Stochastic Oscillator
  • GNPX 39.89
  • ZBAI 59.62

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About ZBAI ATIF Holdings Limited Ordinary Shares

ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.

Share on Social Networks: